Ursodeoxycholic Acid (UDCA) Initiation and Escalation in Primary Biliary Cholangitis (PBC)

Target Audience

This educational activity will address identified knowledge and practice gaps among gastroenterologists, hepatologists, and specialist nurse practitioners (NPs) and physician associates (PAs) related to the management of primary biliary cholangitis (PBC).

Learning Objective

Upon completion of this activity, participants should be better able to:

• Adopt evidence-based monitoring practices upon UDCA initiation to ensure regular assessment of clinical symptoms, biochemical treatment response, and potential need to escalate or adjust therapy

Program Overview

This Insights to Impact™ program, designed for specialists, serves as the second activity in a comprehensive educational series focused on improving the timely recognition and management of PBC. In this activity, learners will focus on first-line standardized therapy for PBC: ursodeoxycholic acid (UDCA). The activity highlights the efficacy of treatment, treatment goals, and monitoring schedules to assess biochemical treatment response and when to escalate therapy.

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, pass the posttest with a 70% score or higher, and submit an evaluation form.

Fee Information

There is no fee for this activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Sonal Kumar, MD, MPH:

• Consulting Fees and Speaker Bureaus: Boehringer Ingelheim, Gilead Sciences, Inc., GlaxoSmithKline, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, Novo Nordisk
• Contracted Research: Gilead Sciences, Inc., Ipsen, Madrigal Pharmaceuticals, Novo Nordisk

Nancy S. Reau, MD:

• Consulting Fees: Arbutus Biopharma, Bluejay Therapeutics, Gilead Sciences, Inc., Salix Pharmaceuticals, Inc., Vir Biotechnology, Inc.
• Contracted Research: AbbVie Inc., Gilead Sciences, Inc. Salix Pharmaceuticals, Inc., Vir Biotechnology, Inc.

The Integritas planners and managers have reported no relevant financial relationships with ineligible companies:

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information 

For information about this activity, please contact us at info@exchangecme.com